Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hypothalamic-pituitary-ovarian axis (HPO axis)
- Target
- HPO axis
- Molecular classification
- Other (system/axis; not a direct molecular classification—individual molecular targets within the axis include G protein-coupled receptors, peptide hormones, steroid receptors)
01
Overview
The **hypothalamic-pituitary-ovarian (HPO) axis** is a central neuroendocrine network essential for regulating female reproduction. It consists of the hypothalamus (releasing GnRH), the anterior pituitary gland (releasing LH and FSH), and the ovaries (secreting estrogens and progesterone). It orchestrates hormonal communication to control the menstrual cycle, ovulation, folliculogenesis, and maintenance of female reproductive function. Disruption of the HPO axis is implicated in numerous reproductive disorders, most notably ovulatory dysfunction and infertility. While many drugs therapeutically manipulate individual components within this axis, the axis itself is not a molecular target but a complex physiological system
- Other names
- Hypothalamic-pituitary-ovarian axisHPO axisHypothalamic-pituitary-gonadal axis (female)Female reproductive axis
02
Mechanism of action
None for the axis as a whole; mechanisms are at nodal targets: - GnRH agonists/antagonists regulate pulsatile GnRH action on the pituitary - Estrogens/progestins manipulate negative/positive feedback to hypothalamus and pituitary - Clomiphene blocks estrogen receptors in the hypothalamus to increase GnRH - Aromatase inhibitors decrease estrogen synthesis - hCG and gonadotropins mimic endogenous hormones
03
Biological functions
Regulation of female reproductive cycle (menstrual/estrous/ovulatory cycles)Hormone secretion (GnRH, LH, FSH, estrogen, progesterone)OvulationFolliculogenesis and oocyte maturationEndometrial regulationFeedback regulation between endocrine glands
04
Disease associations
Infertility and subfertility (ovulatory dysfunction)Polycystic ovary syndrome (PCOS)Primary ovarian insufficiency (POI)Hypogonadotropic hypogonadismPremature ovarian failureEndocrine disordersOther reproductive endocrine disorders
05
Safety considerations
Dysregulation can cause infertility, ovarian hyperstimulation, menstrual disturbancesTherapy risks: ovarian hyperstimulation syndrome (OHSS), thromboembolic risk with estrogens, menopausal symptoms with GnRH analogs
06
Interacting drugs
None as a system; however, drugs interact with key nodes (see below for examples)
7 more in the full profile.
07
Biomarkers
Circulating FSH, LH, estradiol, progesterone (for ovarian reserve and ovulatory status)Anti-Müllerian hormone (AMH)Inhibin B (for ovarian function)
Beyond the preview
Go deeper on Hypothalamic-pituitary-ovarian axis (HPO axis).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hypothalamic-pituitary-ovarian axis (HPO axis).